LLY | Eli Lilly & Co. | $1.3t | $1383.34 | -2.1% | 1.9M |
RVMD | Revolution Medicines, Inc. Common Stock | $41.6b | $160.29 | -1.8% | 1.6M |
INCY | Incyte Genomics Inc | $24.0b | $118.07 | -0.8% | 644.9K |
EXEL | Exelixis Inc | $17.6b | $68.20 | +0.1% | 1.3M |
JAZZ | Jazz Pharmaceuticals, Inc. | $14.9b | $246.88 | +2.2% | 437.2K |
HALO | Halozyme Therapeutics, Inc. | $14.6b | $95.85 | 0.0% | 1.1M |
NUVL | Nuvalent, Inc. Class A Common Stock | $9.8b | $123.96 | 0.0% | N/A |
CORT | Corcept Therapeutics Inc. | $8.9b | $67.84 | -3.0% | 447.2K |
COGT | Cogent Biosciences, Inc. Common Stock | $5.4b | $27.87 | +0.2% | 2.2M |
ERAS | Erasca, Inc. Common Stock | $5.1b | $13.79 | -2.0% | 6.9M |
TNGX | Tango Therapeutics, Inc. | $3.9b | $21.87 | -1.0% | 1.9M |
RLAY | Relay Therapeutics, Inc. Common Stock | $3.8b | $16.49 | +0.0% | 1.8M |
PBLS | Parabilis Medicines, Inc. Common Stock | $3.6b | $28.49 | +0.7% | 459.3K |
CELC | Celcuity Inc. Common Stock | $3.4b | $55.91 | -3.5% | 614.8K |
ELVN | Enliven Therapeutics, Inc. Common Stock | $3.2b | $45.01 | -3.7% | 599.5K |
IDYA | IDEAYA Biosciences, Inc. Common Stock | $3.0b | $26.36 | -4.6% | 1.1M |
NRIX | Nurix Therapeutics, Inc. Common stock | $2.8b | $14.08 | -1.9% | 1.7M |
IMNM | Immunome, Inc. | $2.4b | $16.82 | -1.4% | 547.0K |
BHVN | Biohaven Ltd. | $2.4b | $12.94 | -2.2% | 1.9M |
DAWN | Day One Biopharmaceuticals, Inc. Common Stock | $2.2b | $21.52 | -0.0% | 3.0M |
ZYME | Zymeworks Inc. | $2.2b | $26.21 | +0.9% | 761.3K |
VIR | Vir Biotechnology, Inc. Common Stock | $1.9b | $9.11 | -1.6% | 1.5M |
URGN | UroGen Pharma Ltd. Ordinary Shares | $1.7b | $29.86 | -0.3% | 734.4K |
NUVB | Nuvation Bio Inc. | $1.6b | $3.81 | -1.7% | 4.5M |
NVCR | NovoCure Limited Ordinary Shares | $1.6b | $10.74 | -3.6% | 961.6K |
TYRA | Tyra Biosciences, Inc. Common Stock | $1.5b | $19.64 | +0.6% | 273.4K |
DMRA | Damora Therapeutics, Inc. Ordinary Shares | $1.4b | $23.16 | +2.6% | 423.1K |
VSTM | Verastem, Inc. | $1.2b | $6.94 | -6.6% | 2.6M |
ORIC | Oric Pharmaceuticals, Inc. Common Stock | $1.0b | $7.67 | -4.5% | 946.3K |
RIGL | Rigel Pharmaceuticals Inc. (New) | $0.9b | $42.68 | -1.4% | 162.4K |
GLUE | Monte Rosa Therapeutics, Inc. Common Stock | $0.9b | $9.13 | +1.4% | 912.4K |
KURA | Kura Oncology, Inc. | $0.9b | $7.39 | -0.9% | 2.0M |
OLMA | Olema Pharmaceuticals, Inc. Common Stock | $0.6b | $7.13 | -0.7% | 776.7K |
AVBP | ArriVent BioPharma, Inc. Common Stock | $0.6b | $10.83 | +1.0% | 2.0M |
NVCT | Nuvectis Pharma, Inc. Common Stock | $0.6b | $20.10 | +4.4% | 145.3K |
GERN | Geron Corp | $0.6b | $0.97 | -4.3% | 28.6M |
FTH | Faeth Therapeutics, Inc. Common Stock | $0.5b | $8.81 | -3.0% | 229.2K |
PBYI | PUMA BIOTECHNOLOGY INC | $0.5b | $7.17 | +0.4% | 290.5K |
DCTH | Delcath Systems Inc | $499.7m | $19.70 | +1.4% | 478.1K |
MNPR | Monopar Therapeutics Inc. Common Stock | $469.1m | $70.94 | -0.7% | 83.3K |
ARVN | Arvinas, Inc | $463.6m | $6.83 | +0.3% | 693.5K |
RLMD | Relmada Therapeutics, Inc. Common Stock | $455.5m | $2.88 | -2.2% | 1.6M |
CCCC | C4 Therapeutics, Inc. | $394.9m | $2.48 | -0.6% | 2.3M |
PRLD | Prelude Therapeutics Incorporated | $301.7m | $3.29 | +0.2% | 156.4K |
IMRX | Immuneering Corporation Class A Common Stock | $238.3m | $3.50 | +0.4% | 602.8K |
TLSI | TriSalus Life Sciences, Inc. Common Stock | $214.3m | $2.44 | +5.0% | 321.4K |
ADCT | ADC Therapeutics SA | $197.9m | $1.33 | -1.9% | 652.7K |
BBOT | BridgeBio Oncology Therapeutics, Inc. Common Stock | $186.0m | $1.81 | -6.7% | 418.3K |
WHWK | Whitehawk Therapeutics, Inc. Common Stock | $176.7m | $3.13 | +1.3% | 205.6K |
ZNTL | Zentalis Pharmaceuticals, Inc. Common Stock | $168.5m | $1.38 | -6.4% | 1.0M |